DREAMM-2: Single-Agent Belantamab Mafodotin in Patients with relapsed refractory multiple myeloma and Renal Impairment
What is the DREAMM-2 Trial?
DREAMM-2 is an open label study of belantamab mafodotin. Patients in the trial had actively progressing multiple myeloma that had worsened despite current standard of care and were randomized to two arms to receive either 2.5 mg/kg or 3.4 mg/kg belantamab mafodotin every three weeks.
In this video:
Dr. Hans Lee (MD Andersen Cancer Center - Houston) explains that a post-hoc analysis of the DREAMM-2 study was conducted to examine renal impairment.
Overall, patients in DREAMM-2 had more advanced disease, poorer prognosis and performance status and also had a greater number of prior lines of therapy in comparison with patients in DREAMM-1, the first time in human study of belantamab mafodotin.
Following treatment with single-agent belantamab mafodotin, patients with mild to moderate renal impairment achieved a similar efficacy and safety profile as patients with normal renal function.
Clinical trial information: NCT03525678
Hans Lee, MD
Dr. Lee is an Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston. See Dr. Hans Lee full bio.